<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20240211060962N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2024-06-01</date_registration>
      <primary_sponsor>Oroumia University of Medical Sciences</primary_sponsor>
      <public_title>Investigating the effect of ferrous sulfate on thyroid function in pregnant women</public_title>
      <acronym></acronym>
      <scientific_title>Investigating the effect of ferrous sulfate on thyroid function in pregnant women with acquired hypothyroidism in the second trimester of pregnancy</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2024-04-20</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>48</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/75534</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: For randomization, we use a table of random numbers. Suppose we are conducting a study in which there are two groups A and B. We assign each odd number to group A and each even number to group B. We close our eyes and Place your finger in the table of random numbers and write down the number of its column and row and specify the direction of your movement in this table. Suppose our starting point is the number 5 at the intersection of column 07 and row 07 and the direction of our movement is horizontal. to the right, so the first patient with the number 5 receives treatment A and we continue in the same way until the end. The allocation of the next patient is not predictable and this allocation is not one in between, Blinding description: One way of blinding is the use of a placebo, that is, an inert substance that has the same taste and smell as Taher, although the use of a placebo in itself does not guarantee that the patients were blinded.</study_design>
      <phase>3</phase>
      <hc_freetext>Primary acquired hypothyroidism.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: At the beginning of the study, 5 cc of blood will be collected from each patient and for testing, it will be done using vidas kits for ferritin and thyroid hormones (one from each kit) and Ferozin method to check serum transferrin and iron (one kit from each). ) and it will be done in a laboratory (Kawsar Women's Comprehensive Laboratory in Urmia). Then, for the intervention group, ferrous sulfate tablets from Rosdaro Pharmaceutical Factory, each tablet containing 50 mg of elemental iron, will be given two tablets equivalent to 100 mg of elemental iron per day. After three months, 5 cc of blood will be collected from each group and the tests will be repeated in the same laboratory with the same kits. Intervention 2: Control group: At the beginning of the study, 5 cc of blood will be collected from each patient and for testing, it will be done using vidas kits for ferritin and thyroid hormones (one from each kit) and Ferozin method to check serum transferrin and iron (one kit from each). ) and it will be done in a laboratory (Kawsar Women's Comprehensive Laboratory in Urmia). And for the control group, two placebo pills will be given daily. After three months, 5 cc of blood will be collected from each group and the tests will be repeated in the same laboratory with the same kits.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
In this study, only a part of the data, such as the information related to the main outcome or the like, can be shared after making people unidentifiable.

When:
The access period starts 3 months after the thesis defense

To whom:
The data of this study will be available only to researchers working in medical and scientific academic institutions

Conditions:
Ethical considerations should be observed in all relevant aspects and analyses

Where to obtain:
Send a message to email
  poormobinaa97@gmail

How to obtain:
Examining the person requesting information and the reason for his request for information, observing ethical considerations and checking in the university council, and sending the information if necessary.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Mobina Pourghahramani</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Hasani Street Kosar Hospital</address>
        <city>Urmia</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>5167869465</zip>
        <telephone>+98 44 3346 8815</telephone>
        <email>pourmobinaaa97@gmail.com</email>
        <affiliation>Oroumia University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Mobina Pourghahramani</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Hasani Street Kosar Hospital</address>
        <city>Urmia</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>5167869465</zip>
        <telephone>+98 44 3346 8815</telephone>
        <email>poourmobinaaa97@gmail.com</email>
        <affiliation>Oroumia University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Age 20 to 35 years
Second trimester pregnancy is considered
Primary acquired thyroid disease
Obtaining informed consent and explanation to patients
The bmi of pregnant mothers is considered within the normal range (18.5-24.5)</inclusion_criteria>
      <agemin>20 years</agemin>
      <agemax>35 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria>Having diabetes and high blood pressure
Suffering from chronic diseases, including chronic kidney failure and liver failure
Getting cancer and neoplasm, especially thyroid cancer
Dissatisfaction of patients</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>E01.8</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Other iodine-deficiency related thyroid disorders and allied conditions</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: At the beginning of the study, 5 cc of blood will be collected from each patient and for testing, it will be done using vidas kits for ferritin and thyroid hormones (one from each kit) and Ferozin method to check serum transferrin and iron (one kit from each). ) and it will be done in a laboratory (Kawsar Women's Comprehensive Laboratory in Urmia). Then, for the intervention group, ferrous sulfate tablets from Rosdaro Pharmaceutical Factory, each tablet containing 50 mg of elemental iron, will be given two tablets equivalent to 100 mg of elemental iron per day. After three months, 5 cc of blood will be collected from each group and the tests will be repeated in the same laboratory with the same kits.</i_keyword>
      <i_keyword>Control group: At the beginning of the study, 5 cc of blood will be collected from each patient and for testing, it will be done using vidas kits for ferritin and thyroid hormones (one from each kit) and Ferozin method to check serum transferrin and iron (one kit from each). ) and it will be done in a laboratory (Kawsar Women's Comprehensive Laboratory in Urmia). And for the control group, two placebo pills will be given daily. After three months, 5 cc of blood will be collected from each group and the tests will be repeated in the same laboratory with the same kits.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Primary outcome variable: pregnant women with primary acquired hypothyroidism or those whose tsh is greater than 4.5 mlU/L. Timepoint: Measurement of thyroid hormones at the beginning of the intervention (before the start) and 2 months after the start of ferrous sulfate. Method of measurement: The method of measurement is through laboratory tests, 5 cc of blood will be taken from each patient, and for the test, vidas kits for thyroid hormones will be taken.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>My financial source is a student, and because I am a campus student, no fees are charged by the university.</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2024-01-29</approval_date>
        <contact_name>Urmia University of Medical Sciences (Research Ethics Committee)</contact_name>
        <contact_address>Hasani Street, Kosar Hospital Urmia West Azarbaijan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
